(40–80 mg/d, flexibly dosed) for an additional 28-week treatment period	placebo	risk of relapse	1105	1352	In the double-blind phase, lurasidone significantly delayed time to relapse compared with placebo (log-rank test, p=0.039), reflecting a 33.7% reduction in risk of relapse (Cox hazard ratio (95% confidence interval), 0.663 (0.447–0.983); p=0.041).
(40–80 mg/d, flexibly dosed) for an additional 28-week treatment period	placebo	time to relapse	1105	1352	In the double-blind phase, lurasidone significantly delayed time to relapse compared with placebo (log-rank test, p=0.039), reflecting a 33.7% reduction in risk of relapse (Cox hazard ratio (95% confidence interval), 0.663 (0.447–0.983); p=0.041).
(40–80 mg/d, flexibly dosed) for an additional 28-week treatment period	placebo	adverse event and extrapyramidal symptoms (EPS)-related adverse events	24235	24352	the incidence of EPS-related adverse events in the double-blind phase was low (4%) and comparable between the groups.
(40–80 mg/d, flexibly dosed) for an additional 28-week treatment period	placebo	adverse event and extrapyramidal symptoms (EPS)-related adverse events	24086	24352	In the double-blind phase, the percentage of patients reporting any adverse event was similar for the lurasidone (53.5%) and placebo (54.6%) groups; the incidence of EPS-related adverse events in the double-blind phase was low (4%) and comparable between the groups.
(40–80 mg/d, flexibly dosed) for an additional 28-week treatment period	placebo	risk of relapse	1132	1351	lurasidone significantly delayed time to relapse compared with placebo (log-rank test, p=0.039), reflecting a 33.7% reduction in risk of relapse (Cox hazard ratio (95% confidence interval), 0.663 (0.447–0.983); p=0.041)
